Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Khoja

P3.04-20 Correlation of Immune-Related Adverse Events and Response From Immune Checkpoint Inhibitors in Patients With Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Related publications

Treatment- And Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Advanced Lung Cancer

Bioscience Reports
BiochemistryCell BiologyMolecular BiologyBiophysics
2020English

Concurrent Therapy With Immune Checkpoint Inhibitors and TNFα Blockade in Patients With Gastrointestinal Immune-Related Adverse Events

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

4) Immune-Related Adverse Events in Endocrine Organs Induced by Immune Checkpoint Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019English

P3.01-04 Immune Checkpoint Inhibitors (ICIs) in NSCLC: Immune Related Adverse Events (irAEs) and Outcomes. A Canadian Single Institution Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Immune-Related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Anticancer Research
MedicineCancer ResearchOncology
2020English

Treatment-Related Adverse Events and Response Rate to Immune Checkpoint Inhibition

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2017English

Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer

Oncologist
Cancer ResearchMedicineOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy